MCRB News and Press, Seres Therapeutics Inc. From 01/23/23

Summary Novartis is one of the world’s most successful pharma companies and it is undergoing a major change to become a pure-play innovative medicines company. Part of this also involves Novartis pursuing a “US-First mindset”, which might prefer money at the expense...

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering ...

– Renowned investigator in microbial genomics to join Seres to advance Company’s efforts to develop novel microbiome therapeutics – – Following successful Data Safety Monitoring Board meeting in December for SER-155 Cohort 1, enrollment of Cohort 2 planned ...

Seres Therapeutics, Inc . (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST. An audio webcast of the presentation...

The following slide deck was published by Seres Therapeutics, Inc. in conjunction with this event. For further details see: Seres Therapeutics (MCRB) Investor Presentation - Slideshow

– Event to highlight recurrent CDI market opportunity and SER-109 launch preparations – Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commerci...

Summary After accepting the BLA for SER-109, the FDA has not announced the need for an expert advisory committee. The FDA provides a firm date (April 26, 2023) for its decision concerning approval of SER-109. Big focus on SER-155 and other bacterial infections to follow SER-10...

Seres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Conference Call November 2, 2022 08:30 ET Company Participants Carlo Tanzi - Head of Investor Relations Eric Shaff - President & Chief Executive Officer Lisa von Moltke - Chief Medical Officer Matthew Henn ...

Seres Therapeutics ( NASDAQ: MCRB ) stock fell ~9% on Wednesday after Q3 results missed estimates. The company saw net loss of -$60M, compared to net income of $68.22M in Q3 2021. Total revenue slumped -97.28% Y/Y to $3.44M, missing estimates. Rese...

Seres Therapeutics press release ( NASDAQ: MCRB ): Q3 GAAP EPS of -$0.49 misses by $0.02 . Revenue of $3.44M (-97.3% Y/Y) misses by $3.57M . As of September 30, 2022, Seres had approximately $233.0M in cash, cash equivalents and marketable securities as compare...